R3Mab was also effective in inhibiting multiple myeloma cells containing the t(4;14)(p16.3;q32) chromosomal translocation that results in the expression of an FGFR3–MMSET fusion protein (Chesi et al., 1998; Qing et al., 2009). The gene discussed is FGFR3; the disease is AL amyloidosis.